These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 8062494

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine.
    Eap CB, Lima CA, Macciardi F, Woggon B, Powell K, Baumann P.
    Ther Drug Monit; 1998 Feb; 20(1):7-13. PubMed ID: 9485547
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH, Wood AJ.
    Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA.
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [Abstract] [Full Text] [Related]

  • 7. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA.
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [Abstract] [Full Text] [Related]

  • 8. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
    Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
    [Abstract] [Full Text] [Related]

  • 9. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
    Sandwall P, Lo MW, Jonzon B, Dalén P, Furtek C, Ritter M, Alván G, McCrea J, Sjöqvist F.
    Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
    Llerena A, Valdivielso MJ, Benítez J, Bertilsson L.
    Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
    [Abstract] [Full Text] [Related]

  • 12. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
    Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L.
    Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [Abstract] [Full Text] [Related]

  • 15. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z, Fiset C, Gilbert M, Moerike K, Bélanger PM, Turgeon J.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [Abstract] [Full Text] [Related]

  • 16. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
    Sohn DR, Kwon JT, Kim HK, Ishizaki T.
    Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
    [Abstract] [Full Text] [Related]

  • 17. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T, Dahl ML, Rägo L, Kiivet R, Sjöqvist F.
    Eur J Clin Pharmacol; 1997 May; 53(3-4):257-60. PubMed ID: 9476041
    [Abstract] [Full Text] [Related]

  • 18. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
    Wang SL, Huang JD, Lai MD, Liu BH, Lai ML.
    Clin Pharmacol Ther; 1993 Apr; 53(4):410-8. PubMed ID: 8097442
    [Abstract] [Full Text] [Related]

  • 19. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
    Tybring G, Böttiger Y, Widén J, Bertilsson L.
    Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
    [Abstract] [Full Text] [Related]

  • 20. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.
    Yasumori T, Murayama N, Yamazoe Y, Kato R.
    Clin Pharmacol Ther; 1990 Mar; 47(3):313-22. PubMed ID: 2311333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.